![United States: Bristol-Myers Squibb And AstraZeneca Settle Anti-PD-L1 Antibody Product Litigation - Goodwin Procter LLP](https://cdn.newsserve.net/ONPglobe256.png)
United States: Bristol-Myers Squibb And AstraZeneca Settle Anti-PD-L1 Antibody Product Litigation - Goodwin Procter LLP
We previously reported on Bristol-Myers Squibb's ("BMS") complaint alleging AstraZeneca's PD-L1 antibody product, IMFINZI (durvalumab), infringed U.S. Patent No. 9,402,899
Full Article